ONWARD MEDICAL BUY | EUR17 The Up-LIFT we have been waiting for
This morning ONWARD’s reported pivotal Up-LIFT trial using ARCEX external Neurostimulation attained its primary endpoint at a clinical relevant threshold. This positive top-line data (stat. sig. in one function and strength endpoint) in the restoration of arm and hand function in patients paralysed in four limbs is likely to be filed in coming months, with further data being disclosed imminently. With key catalysts upcoming like i) Up-LIFT data presentation in the coming months, ii) observational data for Home use, and iii) STIMO-HEMO/Hem-ON data enrolling we expect this datapoint could be the first of many highlighting the transformative ARC platform. We reiterate our Buy rating and EUR17 TP.
Since 1996, Bryan, Garnier & Co has been growing with an absolute conviction that the investment banking landscape would experience a major revolution: most of the large local generalist banking groups will disappear to the benefit of a handful of global powerhouses, and an emerging group of independent, highly specialised boutique investment banks.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.